Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-Throughput Drug Screening identifies Pazopanib and Clofilium tosylate as effective treatments for malignant rhabdoid tumors

ABSTRACT: mRNA expression in two different cell lines (DEV and G401) and two conditions (CLOFILIUM and DMSO) were assessed using the Illumina HiSeq2500 plateform in order to detect genes that are differentially expressed in CLOFILIUM condition compared to control (DMSO)

ORGANISM(S): Homo sapiens

PROVIDER: GSE102467 | GEO | 2017/11/02

SECONDARY ACCESSION(S): PRJNA397908

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

High-Throughput Drug Screening identifies Pazopanib and Clofilium tosylate as effective treatments for malignant rhabdoid tumors

Project description:We used microarrays to compared gene re-expression of SMARCB1 in I2A SMARCB1-deficient rhabdoid tumor cell line.

2017-11-02 | GSE98277 | GEO

Analysis of gene expression in human malignant rhabdoid cells following prolonged treatment with the histone deacetylase inhibitor, Panobinostat

Project description:We hypothesized that prolonged treatment of malignant rhabdoid tumor cells with low-dose HDACi will drive cellular differentiation. We assessed changes in gene expression following 21 days treatment with the HDACi, Panobinostat, versus a DMSO vehcile control in three human MRT cell lines. Total RNA obtained from three human malignant rhabdoid tumor cell lines (G401, SJSC, STM91-01) cultured for 21 days in the presence of low-dose Panobinostat was compared to 21-day treated DMSO control cells. All treatments and cell lines were performed in triplicate.

2016-03-01 | E-GEOD-76664 | biostudies-arrayexpress

Analysis of gene expression in human malignant rhabdoid cells following prolonged treatment with the histone deacetylase inhibitor, Panobinostat

2016-03-01 | GSE76664 | GEO

Methylation profiling of Malignant Rhabdoid Tumours

Project description:An observational experiment to methylation profile 79 SMARCB1 negative primary tumours from patients diagnosed with Malignant Rhabdoid Tumours.

2020-07-15 | E-MTAB-6708 | biostudies-arrayexpress

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.

Project description: Not available

| S-EPMC6497578 | biostudies-literature

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.

Project description: Not available

| S-EPMC3408754 | biostudies-literature

Case Analysis of 14 Children with Malignant Rhabdoid Tumor of the Kidney.

Project description: Not available

| S-EPMC8232862 | biostudies-literature

High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors.

Project description: Not available